Call Options

13 transactions
Quarter Operation Price Per call calls change calls Held SEC Form
Q3 2022

Sep 21, 2023

SELL
$31.97 - $49.37 $297,321 - $459,141
-9,300 Reduced 9.67%
86,900 $2.82 Million
Q3 2022

Nov 14, 2022

BUY
$31.97 - $49.37 $2.78 Million - $4.29 Million
86,900 New
86,900 $2.82 Million
Q1 2022

May 16, 2022

SELL
$57.56 - $82.54 $5.54 Million - $7.94 Million
-96,200 Closed
0 $0
Q4 2021

Sep 21, 2023

BUY
$72.5 - $100.68 $6.21 Million - $8.63 Million
85,700 Added 816.19%
96,200 $7.49 Million
Q4 2021

Feb 14, 2022

BUY
$72.5 - $100.68 $6.21 Million - $8.63 Million
85,700 Added 816.19%
96,200 $7.49 Million
Q3 2021

Sep 21, 2023

SELL
$90.24 - $124.05 $7.01 Million - $9.64 Million
-77,700 Reduced 88.1%
10,500 $1 Million
Q3 2021

Nov 15, 2021

SELL
$90.24 - $124.05 $7.01 Million - $9.64 Million
-77,700 Reduced 88.1%
10,500 $1 Million
Q1 2021

Sep 21, 2023

BUY
$116.57 - $155.01 $151,541 - $201,513
1,300 Added 1.5%
88,200 $11.6 Million
Q1 2021

May 14, 2021

BUY
$116.57 - $155.01 $3.94 Million - $5.24 Million
33,800 Added 62.13%
88,200 $11.6 Million
Q4 2019

Feb 13, 2020

BUY
$77.66 - $99.74 $1.12 Million - $1.44 Million
14,400 Added 36.0%
54,400 $5.03 Million
Q2 2019

Aug 14, 2019

BUY
$89.51 - $118.04 $241,677 - $318,708
2,700 Added 7.24%
40,000 $4.72 Million
Q4 2018

Feb 14, 2019

BUY
$56.04 - $82.66 $1.53 Million - $2.26 Million
27,300 Added 273.0%
37,300 $2.35 Million
Q3 2018

Nov 14, 2018

BUY
$48.29 - $80.6 $482,900 - $806,000
10,000 New
10,000 $789,000

Others Institutions Holding EXAS

About EXACT SCIENCES CORP


  • Ticker EXAS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Diagnostics & Research
  • Shares Outstandng 176,960,000
  • Market Cap $8.73B
  • Description
  • Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX, a gene expression tests for...
More about EXAS
Track This Portfolio

Track Jefferies Group LLC Portfolio

Follow Jefferies Group LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Jefferies Group LLC, based on Form 13F filings with the SEC.

News

Stay updated on Jefferies Group LLC with notifications on news.